Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free CDNA Stock Alerts

CareDx (CDNA) Financials

CareDx logo
$50.88 +1.02 (+2.05%)
As of 09/4/2026 04:00 PM Eastern
Compare
Annual Income Statements for CareDx

Annual Income Statements for CareDx

This table shows CareDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -14 -39 -55 -47 -22 -19 -31 -77 -190 53 -21
Consolidated Net Income / (Loss)		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Net Income / (Loss) Continuing Operations		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Total Pre-Tax Income 		-14 -41 -57 -48 -24 -20 -32 -76 -190 53 -21
Total Operating Income		 -12 -37 -20 -16 -25 -23 -30 -77 -203 41 -31
Total Gross Profit		 18 20 27 44 82 129 199 210 178 224 257
Total Revenue		 28 41 48 77 127 192 296 322 280 334 380
Operating Revenue		 28 41 48 77 127 192 296 322 280 334 380
Total Cost of Revenue		 10 21 21 33 45 63 97 112 102 110 123
Operating Cost of Revenue		 10 21 21 33 45 63 97 112 102 110 123
Total Operating Expenses		 30 57 47 59 106 152 229 287 382 183 287
Selling, General & Admin Expense		 12 21 20 23 37 49 75 100 119 125 108
Marketing Expense		 8.35 11 13 22 39 54 77 96 84 82 103
Research & Development Expense		 9.33 12 12 15 31 49 77 90 82 73 71
Other Special Charges / (Income)		 -0.13 -0.46 - - - - 0.00 0.00 96 -96 5.71
Total Other Income / (Expense), net		 -1.78 -4.03 -37 -33 0.59 2.78 -2.36 1.00 13 12 9.70
Interest & Investment Income		 -1.59 -1.86 -5.86 -3.70 0.99 0.27 0.16 3.76 12 12 9.17
Other Income / (Expense), net		 -0.19 -2.17 -31 -23 -0.40 2.51 -2.52 -2.77 1.35 0.33 0.52
Income Tax Expense		 0.00 -1.61 -1.71 -1.43 -1.98 -1.04 -1.43 0.38 0.14 0.31 0.27
Basic Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $1.00 ($0.40)
Weighted Average Basic Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 52.77M 53.29M
Diluted Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $0.93 ($0.40)
Weighted Average Diluted Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 56.62M 53.29M
Weighted Average Basic & Diluted Shares Outstanding		 11.80M 16.50M 23.30M 35.70M 42.88M 51.82M 53.03M 53.67M 51.78M 55.43M 51.22M

Quarterly Income Statements for CareDx

This table shows CareDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -118 -20 -4.62 -11 78 -10 -8.57 1.68 -4.11 2.81 112
Consolidated Net Income / (Loss)		 -118 -20 -4.62 -11 78 -10 -8.57 1.68 -4.11 2.81 111
Net Income / (Loss) Continuing Operations		 -118 -20 -4.62 -11 78 -10 -8.57 1.68 -4.11 2.81 112
Total Pre-Tax Income 		-118 -20 -4.60 -10 78 -10 -8.69 1.66 -3.76 2.78 115
Total Operating Income		 -123 -23 -7.33 -14 75 -13 -11 -0.25 -6.04 1.20 113
Total Gross Profit		 40 46 64 55 58 56 58 69 73 84 229
Total Revenue		 66 72 92 83 87 85 87 100 108 118 264
Operating Revenue		 66 72 92 83 87 85 87 100 108 118 264
Total Cost of Revenue		 26 26 28 28 28 28 29 31 36 34 35
Operating Cost of Revenue		 26 26 28 28 28 28 29 31 36 34 35
Total Operating Expenses		 163 69 72 69 -16 70 69 70 79 83 115
Selling, General & Admin Expense		 27 30 31 32 41 23 28 28 29 30 41
Marketing Expense		 20 20 21 20 21 23 24 24 31 30 33
Research & Development Expense		 18 19 20 17 17 19 17 17 19 21 22
Other Operating Expenses / (Income)		 - - - - - - 0.00 - - - 19
Other Special Charges / (Income)		 - 0.00 0.00 0.00 - 5.36 0.35 0.00 - 0.60 0.00
Total Other Income / (Expense), net		 4.70 2.60 2.73 3.28 3.49 3.08 2.44 1.91 2.28 1.58 2.59
Interest & Investment Income		 3.16 2.89 2.83 3.00 3.05 2.78 2.36 2.01 2.01 1.91 1.74
Other Income / (Expense), net		 1.54 -0.29 -0.10 0.28 0.44 0.30 0.07 -0.11 0.26 -0.33 0.86
Income Tax Expense		 0.17 -0.08 0.02 0.20 0.17 0.06 -0.12 -0.02 0.35 -0.03 3.88
Basic Earnings per Share		 ($2.21) ($0.38) ($0.09) ($0.20) $1.49 ($0.19) ($0.16) $0.03 ($0.08) $0.05 $2.15
Weighted Average Basic Shares Outstanding		 53.76M 51.69M 52.20M 52.90M 52.77M 55.26M 54.30M 52.51M 53.29M 51.15M 51.47M
Diluted Earnings per Share		 ($2.21) ($0.38) ($0.09) ($0.20) $1.42 ($0.19) ($0.16) $0.03 ($0.08) $0.05 $2.07
Weighted Average Diluted Shares Outstanding		 53.76M 51.69M 52.20M 52.90M 56.62M 55.26M 54.30M 53.74M 53.29M 53.13M 53.42M
Weighted Average Basic & Diluted Shares Outstanding		 51.78M 52.08M 52.74M 53.63M 55.43M 55.68M 53.23M 51.43M 51.22M 51.66M 51.73M

Annual Cash Flow Statements for CareDx

This table details how cash moves in and out of CareDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -6.54 -13 8.97 38 -25 96 214 -258 -7.66 32 -49
Net Cash From Operating Activities		 -9.75 -17 -14 -4.01 -2.77 33 -19 -25 -18 38 42
Net Cash From Continuing Operating Activities		 -9.75 -17 -14 -4.01 -2.77 33 -19 -25 -18 38 42
Net Income / (Loss) Continuing Operations		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Consolidated Net Income / (Loss)		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Depreciation Expense		 0.80 2.92 3.73 4.22 5.52 7.01 8.80 12 14 14 15
Amortization Expense		 0.12 4.03 3.87 2.47 1.62 2.54 4.22 4.80 0.51 6.18 6.67
Non-Cash Adjustments To Reconcile Net Income		 1.34 15 34 36 22 25 40 48 48 66 37
Changes in Operating Assets and Liabilities, net		 1.70 1.02 0.05 0.15 -10 18 -42 -13 109 -101 4.53
Net Cash From Investing Activities		 -1.20 -21 -6.11 -7.93 -23 -100 48 -229 40 -0.48 2.16
Net Cash From Continuing Investing Activities		 -1.20 -21 -6.11 -7.93 -23 -100 48 -229 40 -0.48 2.16
Purchase of Property, Plant & Equipment		 -1.20 -0.55 -0.19 -2.04 -2.20 -7.11 -14 -21 -8.34 -6.48 -5.91
Acquisitions		 - 0.00 -5.92 -5.89 -20 -3.25 -22 -3.71 -7.58 0.00 -0.68
Purchase of Investments		 - - - 0.00 0.00 -90 -5.50 -315 -202 -161 -146
Sale and/or Maturity of Investments		 - - - - 0.00 0.00 89 112 258 167 155
Net Cash From Financing Activities		 4.41 25 29 50 -0.13 163 186 -4.54 -30 -5.61 -93
Net Cash From Continuing Financing Activities		 4.41 25 29 50 -0.13 163 186 -4.54 -30 -5.61 -93
Repurchase of Common Equity		 - - - - - 0.00 0.00 -0.64 -28 -0.52 -88
Issuance of Common Equity		 0.20 8.23 18 53 0.76 160 191 2.23 1.50 1.40 2.27
Other Financing Activities, net		 0.05 0.02 1.25 12 -0.72 3.83 -5.29 -6.12 -3.56 -6.48 -7.90
Effect of Exchange Rate Changes		 0.00 - - 0.00 - 0.27 -0.30 0.02 -0.11 0.53 -0.09
Cash Income Taxes Paid		 - - - 0.00 0.00 0.08 0.01 0.39 0.74 0.32 0.28

Quarterly Cash Flow Statements for CareDx

This table details how cash moves in and out of CareDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 6.22 11 2.49 -0.38 19 -26 -21 23 -26 12 296
Net Cash From Operating Activities		 -8.38 -15 19 13 22 -27 9.90 37 21 4.33 31
Net Cash From Continuing Operating Activities		 -8.38 -15 19 13 22 -27 9.90 37 21 4.33 31
Net Income / (Loss) Continuing Operations		 -118 -20 -1.39 -7.41 78 -10 -8.57 1.68 -4.11 2.81 111
Consolidated Net Income / (Loss)		 -118 -20 -1.39 -7.41 78 -10 -8.57 1.68 -4.11 2.81 111
Depreciation Expense		 3.63 3.82 3.54 3.47 3.36 3.60 3.72 3.81 3.88 3.90 2.81
Amortization Expense		 -0.10 2.85 0.78 1.78 0.77 2.18 1.06 2.28 1.16 2.33 1.74
Non-Cash Adjustments To Reconcile Net Income		 8.50 17 13 14 26 8.92 9.42 11 8.09 9.94 -102
Changes in Operating Assets and Liabilities, net		 98 -19 2.85 0.99 -87 -31 4.26 19 12 -15 18
Net Cash From Investing Activities		 41 28 -12 -14 -2.11 1.33 23 12 -35 11 281
Net Cash From Continuing Investing Activities		 41 28 -12 -14 -2.11 1.33 23 12 -35 11 281
Purchase of Property, Plant & Equipment		 -1.59 -1.49 -1.79 -1.69 -1.52 -1.63 -1.01 -1.31 -1.97 -3.82 -1.86
Purchase of Investments		 -9.03 -58 -35 -50 -18 -52 -15 -17 -62 -40 -2.00
Sale and/or Maturity of Investments		 52 87 26 37 17 55 39 31 29 55 120
Net Cash From Financing Activities		 -27 -1.28 -4.85 1.42 -0.90 -0.64 -54 -26 -12 -2.91 -15
Net Cash From Continuing Financing Activities		 -27 -1.28 -4.85 1.42 -0.90 -0.64 -54 -26 -12 -2.91 -15
Issuance of Common Equity		 - 0.53 - 0.87 - 0.87 1.40 - - 0.99 1.51
Other Financing Activities, net		 -0.91 -1.29 -4.85 0.56 -0.90 -1.52 -5.21 -0.92 -0.26 -3.90 -4.77
Effect of Exchange Rate Changes		 0.11 0.03 0.02 0.08 0.41 -0.08 -0.01 -0.01 0.01 0.01 -0.01

Annual Balance Sheets for CareDx

This table presents CareDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 56 77 84 131 152 369 567 543 467 491 413
Total Current Assets		 34 27 27 81 72 273 433 388 314 352 257
Cash & Equivalents		 30 17 17 65 38 135 348 90 82 115 65
Short-Term Investments		 - - - - 0.00 90 0.00 203 153 146 112
Accounts Receivable		 2.37 2.77 2.99 9.76 24 35 60 66 51 65 43
Inventories, net		 0.77 5.46 5.53 4.94 6.01 10 17 19 19 20 27
Prepaid Expenses		 1.34 1.19 1.35 1.80 3.63 3.76 7.93 9.22 7.76 7.07 11
Plant, Property, & Equipment, net		 2.43 2.93 2.08 0.00 0.00 0.00 0.00 0.00 35 34 33
Total Noncurrent Assets		 19 47 55 50 80 95 133 155 118 106 123
Long-Term Investments		 - - - - - - - - - 0.00 24
Goodwill		 12 14 12 12 24 24 37 38 40 40 40
Intangible Assets		 6.65 33 33 33 46 44 50 43 46 38 32
Other Noncurrent Operating Assets		 0.20 0.02 - 4.13 10 27 46 74 31 27 26
Other Noncurrent Nonoperating Assets		 - 0.14 9.58 0.19 0.26 0.27 0.21 0.52 0.59 0.59 0.55
Total Liabilities & Shareholders' Equity		 56 77 84 131 152 369 567 543 467 491 413
Total Liabilities		 26 57 90 35 53 91 101 112 205 113 110
Total Current Liabilities		 10 41 43 20 35 69 77 76 78 89 90
Accounts Payable		 1.64 3.07 3.39 4.71 5.51 9.65 13 9.94 13 7.69 9.99
Accrued Expenses		 3.13 5.58 3.74 5.64 17 21 38 49 45 43 42
Current Employee Benefit Liabilities		 2.37 3.85 5.01 9.16 12 18 26 17 20 38 38
Total Noncurrent Liabilities		 16 16 47 15 18 22 23 36 127 23 20
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 6.06 4.93 2.97 1.97 1.30 0.42 0.00 0.14 0.16 0.18
Other Noncurrent Operating Liabilities		 0.98 6.92 22 12 16 20 23 36 127 23 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 29 20 -5.95 96 99 278 466 431 261 378 303
Total Preferred & Common Equity		 29 19 -6.13 96 99 278 466 431 261 378 303
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 29 19 -6.13 96 99 278 466 431 261 378 303
Common Stock		 203 236 264 412 438 632 854 899 947 1,013 928
Retained Earnings		 -173 -213 -268 -312 -334 -353 -383 -460 -678 -626 -619
Accumulated Other Comprehensive Income / (Loss)		 0.00 -3.66 -2.35 -4.28 -5.21 -2.10 -4.67 -7.50 -6.96 -8.57 -5.52

Quarterly Balance Sheets for CareDx

This table presents CareDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 528 515 501 452 467 477 490 444 432 411 533
Total Current Assets		 371 361 345 303 321 334 350 307 300 269 429
Cash & Equivalents		 75 88 76 93 96 95 89 68 91 78 374
Short-Term Investments		 211 195 192 123 133 145 142 118 103 109 0.00
Accounts Receivable		 59 52 52 60 66 67 71 67 48 45 34
Inventories, net		 18 19 18 20 19 19 23 28 28 26 6.98
Prepaid Expenses		 8.16 7.68 7.31 6.90 6.34 7.34 25 26 30 11 14
Plant, Property, & Equipment, net		 0.00 0.00 0.00 34 34 34 33 32 31 33 27
Total Noncurrent Assets		 157 154 156 115 112 109 107 105 101 109 77
Long-Term Investments		 - - - - - - - - - 11 0.00
Goodwill		 40 40 40 40 40 40 40 40 40 40 36
Intangible Assets		 46 44 46 43 42 40 37 36 33 32 19
Other Noncurrent Operating Assets		 71 70 69 31 29 28 29 28 27 25 22
Other Noncurrent Nonoperating Assets		 0.52 0.58 0.58 0.58 0.59 0.59 0.55 0.55 0.55 0.55 0.52
Total Liabilities & Shareholders' Equity		 528 515 501 452 467 477 490 444 432 411 533
Total Liabilities		 108 110 107 196 202 204 110 117 121 98 107
Total Current Liabilities		 72 74 73 70 78 81 85 93 99 79 94
Accounts Payable		 13 9.88 8.97 9.98 5.87 6.24 8.07 9.86 12 9.07 9.49
Accrued Expenses		 47 50 47 46 47 45 43 44 44 50 50
Current Employee Benefit Liabilities		 12 14 17 15 25 30 14 19 23 21 35
Total Noncurrent Liabilities		 36 35 34 125 122 121 25 24 22 18 14
Noncurrent Deferred & Payable Income Tax Liabilities		 - 0.05 0.14 0.04 0.05 0.20 0.13 0.13 0.12 0.13 0.09
Other Noncurrent Operating Liabilities		 36 35 34 125 122 121 25 24 22 18 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 420 405 394 256 265 273 379 327 311 314 426
Total Preferred & Common Equity		 420 405 394 256 265 273 379 327 311 314 426
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 420 405 394 256 265 273 379 327 311 314 426
Common Stock		 912 924 937 960 969 985 1,023 1,029 1,036 1,052 931
Retained Earnings		 -485 -510 -534 -695 -697 -704 -637 -695 -719 -733 -505
Accumulated Other Comprehensive Income / (Loss)		 -7.44 -8.45 -8.67 -8.11 -7.96 -7.18 -7.09 -6.11 -5.96 -6.27 0.00

Annual Metrics And Ratios for CareDx

This table displays calculated financial ratios and metrics derived from CareDx's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3.07% 44.37% 18.93% 58.45% 65.95% 51.25% 54.22% 8.57% -12.89% 19.07% 13.79%
EBITDA Growth		 -665.72% -190.47% -33.17% 26.06% 44.50% 41.10% -83.58% -230.66% -194.21% 132.85% -113.94%
EBIT Growth		 -967.57% -225.92% -28.97% 23.97% 35.63% 19.70% -61.07% -148.07% -152.53% 120.34% -173.63%
NOPAT Growth		 -1,054.56% -212.87% 45.64% 23.24% -57.48% 8.17% -31.95% -159.81% -163.32% 128.47% -153.17%
Net Income Growth		 -1,855.06% -190.04% -39.75% 15.80% 53.04% 14.81% -63.85% -149.86% -148.37% 127.62% -140.64%
EPS Growth		 -1,260.00% -106.03% 0.42% 44.96% 60.31% 23.08% -47.50% -144.07% -145.83% 126.27% -143.01%
Operating Cash Flow Growth		 -191.10% -69.43% 13.41% 71.99% 30.90% 1,307.33% -157.71% -30.81% 27.14% 306.92% 10.47%
Free Cash Flow Firm Growth		 63.97% -398.86% 128.23% -485.91% -15.30% 82.92% -972.11% 13.02% 59.05% -69.02% 89.23%
Invested Capital Growth		 -5.65% 71.26% -93.80% 1,808.03% 94.48% -12.91% 122.33% 17.17% -81.56% 362.78% -13.67%
Revenue Q/Q Growth		 -4.43% 11.56% 3.52% 16.79% 10.73% 6.22% 12.16% 0.99% -5.66% 6.72% 6.09%
EBITDA Q/Q Growth		 -62.11% -86.67% -49.56% 47.39% -23.60% 32.43% -399.84% -4.37% -118.37% 145.42% -110.56%
EBIT Q/Q Growth		 -72.13% -72.26% -39.46% 43.15% -21.08% 18.71% -103.30% -3.84% -100.12% 126.49% -150.15%
NOPAT Q/Q Growth		 -69.46% -62.79% 41.80% 10.73% -14.62% 67.69% -208.83% -5.06% -103.67% 136.98% -136.18%
Net Income Q/Q Growth		 -53.13% -38.02% -40.15% 37.34% -4.85% 6.29% -70.10% -2.93% -110.22% 136.60% -130.31%
EPS Q/Q Growth		 -397.44% -6.22% -46.01% 48.43% -8.33% 13.04% -78.79% -2.13% -111.98% 134.44% -131.25%
Operating Cash Flow Q/Q Growth		 -50.08% 5.25% 5.99% 50.86% -987.50% 32.84% -18.52% 10.68% -551.59% 389.17% -1.24%
Free Cash Flow Firm Q/Q Growth		 0.00% 10.22% 364.04% -74.68% -16.53% 83.08% -144.01% 15.71% 39.32% -196.21% 76.68%
Invested Capital Q/Q Growth		 -1.97% -35.71% -92.03% -0.82% 7.37% -3.44% 7.84% -5.44% -79.80% 253.95% -13.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.50% 48.02% 55.78% 56.92% 64.23% 67.16% 67.14% 65.13% 63.61% 67.16% 67.55%
EBITDA Margin		 -39.82% -80.12% -89.71% -41.86% -14.00% -5.45% -6.49% -19.76% -66.75% 18.42% -2.26%
Operating Margin		 -42.40% -91.88% -42.00% -20.35% -19.31% -11.72% -10.03% -24.00% -72.55% 12.21% -8.10%
EBIT Margin		 -43.06% -97.22% -105.43% -50.59% -19.62% -10.42% -10.88% -24.86% -72.06% 12.31% -7.97%
Profit (Net Income) Margin		 -48.70% -97.85% -114.97% -61.10% -17.29% -9.74% -10.34% -23.81% -67.88% 15.74% -5.62%
Tax Burden Percent		 100.00% 96.12% 97.02% 97.03% 91.74% 94.75% 95.56% 100.50% 100.07% 99.41% 101.29%
Interest Burden Percent		 113.09% 104.71% 112.41% 124.48% 96.05% 98.65% 99.50% 95.30% 94.13% 128.63% 69.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.59% 0.00%
Return on Invested Capital (ROIC)		 -52.80% -125.45% -101.71% -66.59% -37.48% -27.85% -24.50% -42.49% -175.07% 56.87% -19.73%
ROIC Less NNEP Spread (ROIC-NNEP)		 -25.45% 233.45% -687.13% 58.80% -28.19% -25.62% -21.06% -35.47% -156.97% 52.04% -19.82%
Return on Net Nonoperating Assets (RNNOA)		 14.08% -35.98% -703.10% -37.40% 14.94% 17.92% 16.25% 25.40% 120.10% -40.44% 13.47%
Return on Equity (ROE)		 -38.72% -161.43% -804.81% -103.99% -22.54% -9.94% -8.25% -17.09% -54.98% 16.43% -6.27%
Cash Return on Invested Capital (CROIC)		 -46.98% -177.99% 74.94% -246.67% -101.64% -14.05% -100.40% -58.30% -37.36% -72.05% -5.06%
Operating Return on Assets (OROA)		 -20.76% -59.69% -63.57% -36.16% -17.66% -7.70% -6.90% -14.42% -40.01% 8.58% -6.69%
Return on Assets (ROA)		 -23.48% -60.07% -69.32% -43.67% -15.56% -7.19% -6.56% -13.81% -37.69% 10.97% -4.72%
Return on Common Equity (ROCE)		 -38.72% -160.51% -778.05% -103.78% -22.54% -9.94% -8.25% -17.09% -54.98% 16.43% -6.27%
Return on Equity Simple (ROE_SIMPLE)		 -46.47% -204.07% 905.77% -48.77% -22.19% -6.74% -6.58% -17.78% -72.81% 13.89% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.35 -26 -14 -11 -17 -16 -21 -54 -142 41 -22
NOPAT Margin		 -29.68% -64.32% -29.40% -14.24% -13.51% -8.21% -7.02% -16.80% -50.78% 12.14% -5.67%
Net Nonoperating Expense Percent (NNEP)		 -27.35% -358.89% 585.42% -125.39% -9.29% -2.24% -3.44% -7.02% -18.10% 4.84% 0.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -12.55% -54.47% 10.71% -7.11%
Cost of Revenue to Revenue		 36.50% 51.98% 44.22% 43.08% 35.77% 32.84% 32.86% 34.87% 36.39% 32.84% 32.45%
SG&A Expenses to Revenue		 43.52% 51.01% 41.58% 30.01% 28.76% 25.39% 25.29% 31.20% 42.05% 37.08% 28.32%
R&D to Revenue		 33.16% 30.48% 25.64% 18.96% 24.17% 25.46% 25.82% 28.09% 29.20% 21.69% 18.81%
Operating Expenses to Revenue		 105.89% 139.90% 97.77% 77.26% 83.53% 78.88% 77.17% 89.13% 136.16% 54.94% 75.66%
Earnings before Interest and Taxes (EBIT)		 -12 -40 -51 -39 -25 -20 -32 -80 -202 41 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -33 -43 -32 -18 -10 -19 -64 -187 61 -8.57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.58 2.95 0.00 10.20 9.25 12.85 5.15 1.42 2.48 3.03 3.20
Price to Tangible Book Value (P/TBV)		 7.03 0.00 0.00 19.30 30.92 17.04 6.34 1.74 3.70 3.83 4.20
Price to Revenue (P/Rev)		 2.71 1.41 4.34 12.77 7.20 18.57 8.10 1.90 2.32 3.44 2.55
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.85 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.58% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.04 2.45 139.32 29.35 14.49 63.45 17.52 2.31 16.34 7.57 7.59
Enterprise Value to Revenue (EV/Rev)		 2.20 1.59 4.70 11.93 6.90 17.40 6.93 0.99 1.48 2.66 2.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.44 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.60 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.90 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 100.03 0.00 0.00 0.00 23.33 18.26
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 21.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.53 1.21 -5.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.44 0.06 -3.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.55 -0.15 1.02 -0.64 -0.53 -0.70 -0.77 -0.72 -0.77 -0.78 -0.68
Leverage Ratio		 1.65 2.69 11.61 2.38 1.45 1.38 1.26 1.24 1.46 1.50 1.33
Compound Leverage Factor		 1.87 2.81 13.05 2.96 1.39 1.36 1.25 1.18 1.37 1.93 0.92
Debt to Total Capital		 34.82% 54.79% 121.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 6.33% 52.27% 55.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 28.48% 2.51% 65.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.64% 0.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 65.18% 44.58% -21.83% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.41 -0.74 -0.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.26 -0.21 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.15 -0.03 -0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.89 -0.92 -2.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.69 -0.26 -1.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.54 -0.04 -1.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.30 -4.66 -4.75 13.71 7.92 23.24 14.44 2.88 -0.36 5.93 3.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.57% 3.32% 0.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.38 0.65 0.62 4.16 2.07 3.95 5.61 5.11 4.02 3.94 2.86
Quick Ratio		 3.18 0.49 0.46 3.81 1.79 3.75 5.28 4.73 3.67 3.64 2.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.43 -37 10 -40 -47 -7.95 -85 -74 -30 -51 -5.53
Operating Cash Flow to CapEx		 -813.34% -3,009.65% -7,691.94% -196.90% -125.81% 470.20% -142.30% -118.86% -220.37% 586.80% 710.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 22.80 -6.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -31.17 -0.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -31.58 -1.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.48 0.61 0.60 0.71 0.90 0.74 0.63 0.58 0.56 0.70 0.84
Accounts Receivable Turnover		 11.14 15.83 16.78 12.01 7.52 6.55 6.28 5.10 4.78 5.77 7.08
Inventory Turnover		 14.15 6.78 3.89 6.30 8.30 7.88 7.16 6.16 5.27 5.63 5.33
Fixed Asset Turnover		 12.81 15.17 19.31 0.00 0.00 0.00 0.00 0.00 0.00 9.70 11.42
Accounts Payable Turnover		 7.41 8.97 6.62 8.14 8.90 8.33 8.47 9.64 8.94 10.67 13.95
Days Sales Outstanding (DSO)		 32.77 23.06 21.75 30.39 48.57 55.72 58.12 71.50 76.41 63.24 51.53
Days Inventory Outstanding (DIO)		 25.79 53.80 93.85 57.94 43.99 46.34 50.97 59.23 69.25 64.88 68.43
Days Payable Outstanding (DPO)		 49.24 40.69 55.13 44.82 41.02 43.83 43.08 37.86 40.82 34.22 26.17
Cash Conversion Cycle (CCC)		 9.32 36.18 60.47 43.50 51.54 58.23 66.00 92.87 104.84 93.90 93.78
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 15 26 1.63 31 61 53 117 137 25 117 101
Invested Capital Turnover		 1.78 1.95 3.46 4.68 2.77 3.39 3.49 2.53 3.45 4.68 3.48
Increase / (Decrease) in Invested Capital		 -0.92 11 -25 29 29 -7.82 64 20 -112 92 -16
Enterprise Value (EV)		 62 64 227 913 877 3,344 2,053 318 414 888 768
Market Capitalization		 76 57 210 978 915 3,569 2,401 611 649 1,148 969
Book Value per Share		 $2.48 $0.92 ($0.21) $2.47 $2.33 $5.64 $8.82 $8.05 $4.83 $7.06 $5.89
Tangible Book Value per Share		 $0.91 ($1.29) ($1.79) $1.30 $0.70 $4.25 $7.17 $6.54 $3.24 $5.59 $4.49
Total Capital		 45 44 28 96 99 278 466 431 261 378 303
Total Debt		 16 24 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 13 1.10 18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -14 6.69 17 -65 -38 -225 -348 -293 -235 -261 -201
Capital Expenditures (CapEx)		 1.20 0.55 0.19 2.04 2.20 7.11 14 21 8.34 6.48 5.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.81 -8.57 -17 -3.01 -1.13 -21 7.57 19 0.22 1.81 -9.93
Debt-free Net Working Capital (DFNWC)		 27 8.69 -0.42 62 37 204 356 312 236 262 167
Net Working Capital (NWC)		 24 -14 -16 62 37 204 356 312 236 262 167
Net Nonoperating Expense (NNE)		 5.35 14 41 36 4.80 2.94 9.85 23 48 -12 -0.19
Net Nonoperating Obligations (NNO)		 -14 6.54 7.59 -65 -38 -225 -349 -294 -236 -261 -202
Total Depreciation and Amortization (D&A)		 0.91 6.95 7.60 6.68 7.14 9.54 13 16 15 20 22
Debt-free, Cash-free Net Working Capital to Revenue		 -9.99% -21.09% -35.83% -3.93% -0.89% -10.83% 2.56% 5.84% 0.08% 0.54% -2.61%
Debt-free Net Working Capital to Revenue		 96.21% 21.38% -0.87% 80.46% 29.19% 106.08% 120.13% 96.92% 84.06% 78.63% 44.04%
Net Working Capital to Revenue		 86.02% -34.85% -33.40% 80.46% 29.19% 106.08% 120.13% 96.92% 84.06% 78.63% 44.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $1.00 ($0.40)
Adjusted Weighted Average Basic Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 52.77M 53.29M
Adjusted Diluted Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $0.93 ($0.40)
Adjusted Weighted Average Diluted Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 56.62M 53.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.97M 16.50M 29.07M 41.73M 42.88M 51.82M 53.03M 53.67M 51.78M 55.43M 51.22M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.44 -17 -13 -11 -17 -16 -21 -54 -73 -53 -18
Normalized NOPAT Margin		 -29.99% -42.67% -26.56% -14.24% -13.51% -8.21% -7.02% -16.80% -26.16% -16.01% -4.62%
Pre Tax Income Margin		 -48.70% -101.80% -118.51% -62.97% -18.85% -10.28% -10.83% -23.69% -67.83% 15.84% -5.55%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -111.00 -6.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -30.95 -1.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -111.40 -7.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -31.35 -2.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.84% -14.47% 0.99% -411.01%

Quarterly Metrics And Ratios for CareDx

This table displays calculated financial ratios and metrics derived from CareDx's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 51,216,344.00 51,659,481.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 51,216,344.00 51,659,481.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.05 2.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -20.41% -6.75% 31.26% 23.35% 32.04% 17.54% -6.06% 20.72% 25.19% 38.99% 204.45%
EBITDA Growth		 -628.78% 41.91% 100.53% 78.44% 167.42% 54.88% -102.29% 170.07% -100.83% 197.21% 1,991.69%
EBIT Growth		 -504.67% 25.35% 84.95% 61.82% 162.04% 42.78% -48.77% 97.37% -106.81% 106.64% 1,132.47%
NOPAT Growth		 -541.38% 20.50% 85.17% 63.55% 186.82% 40.73% -51.78% 97.42% -105.02% 112.94% 1,505.13%
Net Income Growth		 -544.32% 29.85% 94.41% 68.46% 166.06% 47.94% -85.33% 115.75% -104.68% 127.13% 1,391.27%
EPS Growth		 -550.00% 27.27% 93.48% 67.44% 164.25% 50.00% -77.78% 115.00% -105.00% 126.32% 1,393.75%
Operating Cash Flow Growth		 -216.65% -2,381.97% 3,897.39% 223.02% 361.17% -73.62% -47.78% 198.34% -2.40% 116.30% 209.29%
Free Cash Flow Firm Growth		 178.00% 732.63% 2,073.64% 27,394.31% -166.36% -251.47% -239.40% -201.04% 253.99% 129.43% 278.00%
Invested Capital Growth		 -81.56% -69.25% -69.80% -73.59% 362.78% 260.08% 281.66% 251.46% -13.67% -22.30% -63.40%
Revenue Q/Q Growth		 -2.42% 9.88% 28.07% -10.18% 4.46% -2.19% 2.35% 15.43% 8.33% 8.59% 124.21%
EBITDA Q/Q Growth		 -410.57% 88.98% 101.00% -3,948.06% 1,696.70% -109.21% 14.12% 191.55% -112.82% 1,064.40% 1,571.29%
EBIT Q/Q Growth		 -352.91% 83.79% 78.61% -143.19% 835.90% -117.41% 15.52% 96.81% -1,536.26% 115.03% 13,042.63%
NOPAT Q/Q Growth		 -326.06% 84.23% 78.81% -156.03% 1,114.77% -112.56% 16.85% 96.81% -1,603.31% 128.66% 8,926.57%
Net Income Q/Q Growth		 -402.86% 85.89% 91.63% -431.42% 1,153.05% -113.27% 17.24% 119.55% -345.25% 168.38% 3,838.63%
EPS Q/Q Growth		 -413.95% 85.52% 90.63% -366.67% 1,114.29% -113.38% 15.79% 118.75% -366.67% 162.50% 4,040.00%
Operating Cash Flow Q/Q Growth		 17.66% -82.70% 223.75% -33.92% 74.80% -221.45% 137.22% 277.54% -42.82% -79.72% 606.30%
Free Cash Flow Firm Q/Q Growth		 8,500.39% 202.13% 4.18% 3.23% -120.42% -569.89% 4.01% 25.12% 114.12% 189.96% 480.66%
Invested Capital Q/Q Growth		 -79.80% 62.17% -10.32% -10.10% 253.95% 26.18% -4.95% -17.21% -13.06% 13.57% -55.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.94% 64.01% 69.71% 66.73% 67.45% 66.45% 66.94% 69.36% 67.24% 71.43% 86.75%
EBITDA Margin		 -179.29% -17.98% 0.14% -5.99% 91.55% -8.62% -7.23% 5.74% -0.68% 6.03% 44.95%
Operating Margin		 -187.03% -26.84% -4.44% -12.66% 86.27% -15.79% -12.83% -0.25% -5.57% 1.02% 42.90%
EBIT Margin		 -184.68% -27.24% -4.55% -12.32% 86.77% -15.44% -12.75% -0.35% -5.33% 0.74% 43.23%
Profit (Net Income) Margin		 -180.11% -23.12% -1.51% -8.94% 90.10% -12.23% -9.88% 1.67% -3.79% 2.39% 41.92%
Tax Burden Percent		 100.14% 99.50% 101.60% 102.77% 99.78% 100.56% 98.65% 100.90% 109.17% 101.15% 96.61%
Interest Burden Percent		 97.39% 85.30% 32.68% 70.60% 104.06% 78.71% 78.60% -470.26% 65.15% 319.93% 100.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.22% 0.00% 0.00% -0.90% 0.00% -1.15% 3.39%
Return on Invested Capital (ROIC)		 -451.35% -59.19% -11.63% -34.98% 403.21% -40.54% -34.51% -1.19% -13.57% 3.23% 254.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 -439.16% -57.95% -12.21% -34.95% 401.81% -40.09% -34.13% -2.07% -13.62% 2.49% 254.31%
Return on Net Nonoperating Assets (RNNOA)		 335.99% 42.98% 9.32% 26.65% -312.30% 28.17% 23.91% 1.54% 9.26% -1.55% -189.46%
Return on Equity (ROE)		 -115.35% -16.21% -2.32% -8.32% 90.91% -12.36% -10.61% 0.35% -4.31% 1.69% 65.29%
Cash Return on Invested Capital (CROIC)		 -37.36% -53.11% -46.94% -21.88% -72.05% -60.56% -65.19% -31.72% -5.06% 16.46% 201.38%
Operating Return on Assets (OROA)		 -102.53% -15.28% -2.75% -7.88% 60.48% -11.36% -9.54% -0.28% -4.48% 0.68% 52.20%
Return on Assets (ROA)		 -100.00% -12.97% -0.91% -5.72% 62.80% -8.99% -7.40% 1.32% -3.18% 2.19% 50.63%
Return on Common Equity (ROCE)		 -115.35% -16.21% -2.32% -8.32% 90.91% -12.36% -10.61% 0.35% -4.31% 1.69% 65.29%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -71.50% -60.32% -52.54% 0.00% 16.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -86 -14 -2.87 -7.34 75 -9.36 -7.78 -0.25 -4.23 1.21 109
NOPAT Margin		 -130.92% -18.79% -3.11% -8.86% 86.08% -11.05% -8.98% -0.25% -3.90% 1.03% 41.45%
Net Nonoperating Expense Percent (NNEP)		 -12.18% -1.25% 0.58% -0.03% 1.40% -0.44% -0.38% 0.88% 0.05% 0.74% 0.45%
Return On Investment Capital (ROIC_SIMPLE)		 -32.85% - - - 19.69% -2.47% -2.38% -0.08% -1.39% 0.39% 25.70%
Cost of Revenue to Revenue		 39.06% 35.99% 30.29% 33.27% 32.55% 33.55% 33.06% 30.64% 32.76% 28.57% 13.25%
SG&A Expenses to Revenue		 40.48% 37.35% 30.00% 34.40% 46.99% 26.89% 31.94% 28.41% 26.46% 25.90% 15.50%
R&D to Revenue		 27.87% 25.97% 21.33% 21.10% 19.09% 21.87% 19.42% 16.76% 17.81% 18.20% 8.48%
Operating Expenses to Revenue		 247.96% 90.84% 74.16% 79.39% -18.82% 82.24% 79.77% 69.61% 72.81% 70.41% 43.75%
Earnings before Interest and Taxes (EBIT)		 -121 -20 -4.20 -10 75 -13 -11 -0.35 -5.78 0.87 114
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -118 -13 0.13 -4.96 79 -7.30 -6.27 5.74 -0.74 7.10 119
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.48 2.14 3.06 6.03 3.03 2.59 3.32 2.49 3.20 2.84 3.46
Price to Tangible Book Value (P/TBV)		 3.70 3.18 4.43 8.55 3.83 3.26 4.33 3.26 4.20 3.69 3.97
Price to Revenue (P/Rev)		 2.32 1.99 2.72 5.27 3.44 2.84 3.19 2.16 2.55 2.15 2.50
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 21.85 15.85 18.71 10.99 0.00 0.00 13.11
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 4.58% 6.31% 5.34% 9.10% 0.00% 0.00% 7.63%
Enterprise Value to Invested Capital (EV/IC)		 16.34 8.09 15.75 42.46 7.57 5.09 6.42 4.98 7.59 6.01 21.36
Enterprise Value to Revenue (EV/Rev)		 1.48 1.21 1.95 4.50 2.66 2.17 2.65 1.62 2.02 1.67 1.86
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 14.44 10.70 13.42 7.15 0.00 118.49 8.40
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 21.60 14.80 19.08 9.61 0.00 0.00 10.10
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 21.90 15.18 19.64 9.73 0.00 0.00 10.54
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 180.76 23.33 28.12 50.88 13.62 18.26 9.47 11.73
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31.95 5.68
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.77 -0.74 -0.76 -0.76 -0.78 -0.70 -0.70 -0.74 -0.68 -0.62 -0.75
Leverage Ratio		 1.46 1.45 1.47 1.47 1.50 1.48 1.54 1.56 1.33 1.30 1.30
Compound Leverage Factor		 1.42 1.24 0.48 1.03 1.56 1.17 1.21 -7.32 0.86 4.16 1.30
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.21 0.61 1.54 4.00 6.16 4.80 4.66 2.89 4.15 4.54 9.47
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.02 4.32 4.09 4.10 3.94 4.11 3.30 3.03 2.86 3.40 4.58
Quick Ratio		 3.67 3.93 3.77 3.78 3.64 3.55 2.72 2.44 2.45 2.93 4.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 26 79 82 85 -17 -116 -112 -84 12 34 199
Operating Cash Flow to CapEx		 -525.78% -1,029.72% 1,058.60% 743.15% 1,438.17% -1,630.92% 982.62% 2,862.68% 1,083.87% 113.46% 1,647.15%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.56 0.56 0.61 0.64 0.70 0.74 0.75 0.79 0.84 0.92 1.21
Accounts Receivable Turnover		 4.78 4.61 5.04 5.29 5.77 5.26 5.11 6.25 7.08 7.11 11.60
Inventory Turnover		 5.27 5.35 5.46 5.75 5.63 5.21 4.78 4.87 5.33 5.21 7.72
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 9.70 10.32 10.31 11.04 11.42 12.53 20.08
Accounts Payable Turnover		 8.94 8.93 13.21 14.08 10.67 12.42 14.33 12.99 13.95 14.99 13.92
Days Sales Outstanding (DSO)		 76.41 79.25 72.36 69.04 63.24 69.35 71.50 58.36 51.53 51.31 31.47
Days Inventory Outstanding (DIO)		 69.25 68.28 66.80 63.48 64.88 70.09 76.30 74.97 68.43 70.09 47.26
Days Payable Outstanding (DPO)		 40.82 40.87 27.64 25.93 34.22 29.38 25.47 28.10 26.17 24.35 26.21
Cash Conversion Cycle (CCC)		 104.84 106.65 111.51 106.59 93.90 110.06 122.33 105.23 93.78 97.05 52.51
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 25 41 37 33 117 148 141 116 101 115 51
Invested Capital Turnover		 3.45 3.15 3.74 3.95 4.68 3.67 3.84 4.79 3.48 3.14 6.15
Increase / (Decrease) in Invested Capital		 -112 -92 -85 -92 92 107 104 83 -16 -33 -89
Enterprise Value (EV)		 414 332 580 1,406 888 753 902 580 768 691 1,099
Market Capitalization		 649 548 809 1,647 1,148 984 1,088 774 969 889 1,472
Book Value per Share		 $4.83 $4.95 $5.08 $5.18 $7.06 $6.84 $5.88 $5.85 $5.89 $6.12 $8.24
Tangible Book Value per Share		 $3.24 $3.33 $3.50 $3.65 $5.59 $5.44 $4.51 $4.46 $4.49 $4.71 $7.18
Total Capital		 261 256 265 273 378 379 327 311 303 314 426
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -235 -216 -229 -241 -261 -231 -186 -194 -201 -198 -374
Capital Expenditures (CapEx)		 1.59 1.49 1.79 1.69 1.52 1.63 1.01 1.31 1.97 3.82 1.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.22 17 13 12 1.81 34 28 7.02 -9.93 3.07 -38
Debt-free Net Working Capital (DFNWC)		 236 233 242 253 262 265 214 201 167 190 336
Net Working Capital (NWC)		 236 233 242 253 262 265 214 201 167 190 336
Net Nonoperating Expense (NNE)		 32 3.12 -1.47 0.06 -3.48 0.99 0.78 -1.92 -0.12 -1.60 -1.25
Net Nonoperating Obligations (NNO)		 -236 -215 -228 -240 -261 -231 -187 -195 -202 -199 -374
Total Depreciation and Amortization (D&A)		 3.53 6.67 4.33 5.25 4.13 5.78 4.78 6.09 5.04 6.23 4.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.08% 6.17% 4.51% 3.77% 0.54% 9.83% 8.17% 1.96% -2.61% 0.74% -6.46%
Debt-free Net Working Capital to Revenue		 84.06% 84.65% 81.55% 80.78% 78.63% 76.48% 62.82% 56.21% 44.04% 46.08% 56.87%
Net Working Capital to Revenue		 84.06% 84.65% 81.55% 80.78% 78.63% 76.48% 62.82% 56.21% 44.04% 46.08% 56.87%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.21) ($0.32) ($0.03) ($0.14) $1.49 ($0.19) ($0.16) $0.03 ($0.08) $0.05 $2.15
Adjusted Weighted Average Basic Shares Outstanding		 53.76M 51.69M 52.20M 52.90M 52.77M 55.26M 54.30M 52.51M 53.29M 51.15M 51.47M
Adjusted Diluted Earnings per Share		 ($2.21) ($0.32) ($0.03) ($0.14) $1.42 ($0.19) ($0.16) $0.03 ($0.08) $0.05 $2.07
Adjusted Weighted Average Diluted Shares Outstanding		 53.76M 51.69M 52.20M 52.90M 56.62M 55.26M 54.30M 53.74M 53.29M 53.13M 53.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 51.78M 52.08M 52.74M 53.63M 55.43M 55.68M 53.23M 51.43M 51.22M 51.66M 51.73M
Normalized Net Operating Profit after Tax (NOPAT)		 -86 -14 -2.82 -7.34 75 -5.61 -7.54 -0.17 -4.23 1.26 109
Normalized NOPAT Margin		 -130.92% -18.79% -3.06% -8.86% 86.08% -6.62% -8.70% -0.17% -3.90% 1.07% 41.45%
Pre Tax Income Margin		 -179.86% -23.24% -1.49% -8.70% 90.30% -12.16% -10.02% 1.66% -3.47% 2.36% 43.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -14.47% -14.94% -17.11% -18.45% 0.99% 0.00% 86.00% 107.26% -411.01% 0.00% 45.04%

Financials Breakdown Chart

Key Financial Trends

CareDx’s Q2 2026 results showed a sharp acceleration in reported revenue and profitability, although the quarter also contains significant cash-flow and noncash items that investors should review carefully. Revenue increased to $263.9 million from $86.7 million in Q2 2025 and $117.7 million in Q1 2026. Gross profit rose to $228.9 million, producing an unusually high gross margin of approximately 86.8%, compared with 66.9% a year earlier. Operating income reached $113.2 million, versus operating losses in each comparable prior-year quarter.

Net income attributable to common shareholders was $111.9 million, or $2.15 per basic share, compared with a loss of $8.6 million, or $0.16 per share, in Q2 2025. CareDx also remained profitable in Q1 2026, although Q2 earnings were substantially higher. The recent improvement represents a major change from the company’s recurring losses during 2022 through 2025, but investors should determine how much of the Q2 result reflects sustainable operating performance versus unusual items.

  • Revenue growth accelerated dramatically. Q2 2026 revenue of $263.9 million was more than triple Q2 2025 revenue of $86.7 million and substantially above the $117.7 million reported in Q1 2026.
  • Profitability improved sharply. Operating income increased from a $11.1 million loss in Q2 2025 to $113.2 million of income in Q2 2026, while net income attributable to common shareholders rose to $111.9 million.
  • Gross margin expanded significantly. Gross profit increased to $228.9 million, implying an approximately 86.8% gross margin versus roughly 66.9% in Q2 2025 and 71.4% in Q1 2026.
  • Operating cash flow was positive. CareDx generated $30.6 million of operating cash flow in Q2 2026, up from $4.3 million in Q1 2026 and $9.9 million in the restated Q2 2025 period.
  • Liquidity strengthened on the reported balance sheet. Cash and equivalents rose to $373.6 million at June 30, 2026, from $77.9 million at March 31, 2026. The company reported no short-term or long-term investments at quarter-end, indicating that much of its liquid portfolio had been converted into cash.
  • CareDx has no reported debt balance in the supplied data. Total liabilities were $107.4 million compared with shareholders’ equity of $425.6 million, supporting a relatively strong balance-sheet position and a current ratio of approximately 4.6.
  • Longer-term revenue trends had been improving before Q2 2026. Quarterly revenue increased from $65.6 million in Q4 2023 to $86.6 million in Q4 2024 and $108.4 million in Q4 2025, suggesting improving commercial momentum even before the latest reported surge.
  • The Q2 cash increase was heavily influenced by investing activity. The cash-flow statement reports $119.7 million of investment sales or maturities and a $280.6 million net investing cash inflow. This suggests that portfolio repositioning or other non-operating activity, rather than core operations alone, contributed materially to the increase in cash.
  • The cash-flow statement contains an apparent reconciliation issue. Operating cash flow of $30.6 million, investing cash flow of $280.6 million, financing cash flow of negative $15.5 million and foreign-exchange effects of negative $9,000 would imply a net cash increase of approximately $295.7 million, which matches the reported cash change. However, the listed investing components do not appear to fully support the reported $280.6 million investing total. Investors should consult the company’s filing for clarification.
  • Profitability and equity quality still require scrutiny. Q2 2026 includes a negative $102.2 million noncash adjustment in the operating cash-flow reconciliation, while retained earnings remained negative at $505.4 million. In addition, Q2 2025 and Q1 2025 results were restated, and the unusually large Q2 2026 earnings increase should not yet be assumed to represent a normalized run rate.

Overall, the statements point to a potentially important inflection in CareDx’s business: revenue, operating income, earnings per share and operating cash flow all improved substantially. The company also ended the quarter with a large cash balance and limited reported liabilities. However, the exceptional size of the Q2 revenue and profit increase, the unusual cash-flow composition and the apparent investing-activity reconciliation issue make it important for investors to separate recurring operating gains from one-time or accounting-related effects.

09/04/26 11:49 PM ETAI Generated. May Contain Errors.

CareDx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CareDx's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

CareDx's net income appears to be on an upward trend, with a most recent value of -$21.35 million in 2025, rising from -$13.71 million in 2015. The previous period was $52.55 million in 2024. Check out CareDx's forecast to explore projected trends and price targets.

CareDx's total operating income in 2025 was -$30.78 million, based on the following breakdown:
  • Total Gross Profit: $256.57 million
  • Total Operating Expenses: $287.35 million

Over the last 10 years, CareDx's total revenue changed from $28.14 million in 2015 to $379.81 million in 2025, a change of 1,249.5%.

CareDx's total liabilities were at $110.13 million at the end of 2025, a 2.2% decrease from 2024, and a 321.2% increase since 2015.

In the past 10 years, CareDx's cash and equivalents has ranged from $16.90 million in 2017 to $348.49 million in 2021, and is currently $65.43 million as of their latest financial filing in 2025.

Over the last 10 years, CareDx's book value per share changed from 2.48 in 2015 to 5.89 in 2025, a change of 137.8%.


Related Companies

Financial statements for NASDAQ:CDNA last updated on 7/30/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel